Earnings ·
Grifols reported first-half 2026 results with total revenue of €3,574 million, up 2.6% at constant currency, driven by…
GRFSGrifols SA
Grifols reported first-half 2026 results with total revenue of €3,574 million, up 2.6% at constant currency, driven by a 5.4% increase in Biopharma segment sales led by immunoglobulins. Net profit rose 28.7% to €227 million, while adjusted EBITDA reached €854 million with a margin of 23.9%. Free cash flow pre-M&A improved significantly to positive €91 million from negative €12 million in the prior year period. The company successfully refinanced all 2027 debt maturities through an upsized €3 billion Term Loan B and increased revolving credit facility, alongside a €500 million redemption of its 2030 bond, extending its maturity profile with no significant maturities until Q4 2028. Grifols confirmed its full-year 2026 guidance and announced an organizational restructuring to create dedicated U.S. and Rest of World Biopharma entities.